Initial PCV Chemotherapy Followed by Radiotherapy Is Associated With a Prolonged Response But Late Neurotoxicity in 20 Diffuse Low-Grade Glioma Patients.
Fiche publication
Date publication
janvier 2022
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TAILLANDIER Luc, Pr MOUREAUX Jean-Marie , Pr GAUCHOTTE Guillaume, Pr VERGER Antoine, Dr RECH Fabien
Tous les auteurs :
Blonski M, Obara T, Brzenczek C, Pouget C, Dillier C, Meyer M, Lavigne L, Forthoffer N, Broussois A, Gauchotte G, Baron MH, Rech F, Mézières S, Gaudeau Y, Verger A, Vogin G, Anxionnat R, Moureaux JM, Taillandier L
Lien Pubmed
Résumé
Study RTOG 9802 in high-risk diffuse low-grade gliomas (DLGGs) showed the potential synergistic effect on survival of the procarbazine, CCNU, and vincristine (PCV) radiotherapy (RT) combination. Limited data on long-term neurocognitive impact and quality of life (QoL) have yet been reported.
Mots clés
chemotherapy, diffuse low-grade glioma, kinetics, neurocognition, neurotoxicity, quality of life, radiotherapy, surgery
Référence
Front Oncol. 2022 ;12:827897